BGLC

Business Context and Reporting Period

Company: BioNexus Gene Lab Corp. (BGLC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2024
Business Overview: BGLC operates in the biochemical industry through two Malaysian subsidiaries: MRNA Scientific (molecular lab for disease detection) and Chemrex (industrial chemical wholesaler). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Segment Performance (Six Months 2024): Chemrex contributed $4,347,754 (99.8%) of total revenue and generated a net profit of $804,393. MRNA Scientific contributed $8,661 (0.2%) of revenue and reported a net loss of $109,699.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 23.1% quarter-over-quarter (Q2 2024 vs. Q2 2023) and 11.9% year-to-date. This was primarily driven by Chemrex's lower selling prices due to market competition.
• Profitability Turnaround: The company reported a net profit of $199,104 for Q2 2024, a significant improvement from a net loss of $259,251 in Q2 2023. Year-to-date net profit was $95,347 compared to a loss of $328,317 in the prior year.
• Other Income Surge: Other income increased 274.1% in Q2 2024 to $730,105, largely due to Chemrex recovering doubtful debt provisions, capital gains on investments, and bank interest.
• Operating Expenses: Total operating expenses decreased 5.9% in Q2 2024 compared to the prior year, driven by reduced provisions for losses and lower director remuneration at Chemrex, partially offset by increased administrative costs at the holding company.
• Cash Flow: Net cash used in operating activities increased to $704,982 for the six months ended June 30, 2024, compared to $140,341 in the prior period, despite the net profit, due to working capital changes and non-cash adjustments.

Outlook, Risks, and Unusual Items

• Nasdaq Compliance: The company received an extension from Nasdaq to regain compliance with the $1.00 minimum bid price rule (Rule 5550(a)(2)) until November 4, 2024. Failure to maintain the price for 10 consecutive business days within this period could result in delisting.
• Strategic Investment: MRNA Scientific announced a strategic investment in Ascension Innovation Sdn Bhd (AISB). As of the filing date, the investment campaign was concluded but the transaction had not yet closed.
• Advisory Agreement: On July 1, 2024, the company entered into an agreement with Maxim Group LLC for M&A and financial advisory services, issuing 300,000 shares of common stock as compensation.
• Supplier Dispute Resolution: A dispute with a supplier regarding hardware delivery was settled in June 2024. The supplier refunded approximately $76,000, which was recorded as a gain/loss adjustment in the income statement.
• Operational Risks: MRNA Scientific's operations continue to face challenges from post-pandemic hesitancy in clinic visits and recent RNA machine breakdowns. Chemrex faces lingering supply chain disruptions and demand declines in the manufacturing sector.

Investor Verification Checklist

• Nasdaq Bid Price: Monitor the daily closing bid price to ensure it meets the $1.00 threshold for 10 consecutive days before November 4, 2024, to avoid delisting.
• Chemrex Revenue Quality: Verify the sustainability of Chemrex's revenue recovery given the cited market competition and lower selling prices.
• Cash Burn Rate: Review the increase in net cash used in operating activities ($704,982 YTD) against the company's assertion that current cash reserves are sufficient for 12 months of operations.
• Investment Closure: Confirm the closing status and terms of the strategic investment in Ascension Innovation Sdn Bhd.
• Related Party Transactions: Note the significant increase in "Amount owing to directors" on the balance sheet (from $13,199 to $215,543) and the issuance of shares to directors and advisors.